JP2025506488A - 治療抗体 - Google Patents

治療抗体 Download PDF

Info

Publication number
JP2025506488A
JP2025506488A JP2024547510A JP2024547510A JP2025506488A JP 2025506488 A JP2025506488 A JP 2025506488A JP 2024547510 A JP2024547510 A JP 2024547510A JP 2024547510 A JP2024547510 A JP 2024547510A JP 2025506488 A JP2025506488 A JP 2025506488A
Authority
JP
Japan
Prior art keywords
sequence
seq
sequence identity
identity
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506488A5 (enExample
Inventor
ロベルト バンディエラ
Original Assignee
ペットメディックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2209454.4A external-priority patent/GB202209454D0/en
Application filed by ペットメディックス・リミテッド filed Critical ペットメディックス・リミテッド
Publication of JP2025506488A publication Critical patent/JP2025506488A/ja
Publication of JP2025506488A5 publication Critical patent/JP2025506488A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024547510A 2022-02-09 2023-02-08 治療抗体 Pending JP2025506488A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2201674.5 2022-02-09
GB202201674 2022-02-09
GBGB2209454.4A GB202209454D0 (en) 2022-06-28 2022-06-28 Therapeutic antibodies
GB2209454.4 2022-06-28
PCT/GB2023/050281 WO2023152486A1 (en) 2022-02-09 2023-02-08 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
JP2025506488A true JP2025506488A (ja) 2025-03-11
JP2025506488A5 JP2025506488A5 (enExample) 2026-01-30

Family

ID=85283675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547510A Pending JP2025506488A (ja) 2022-02-09 2023-02-08 治療抗体

Country Status (11)

Country Link
US (1) US20250340659A1 (enExample)
EP (1) EP4476256A1 (enExample)
JP (1) JP2025506488A (enExample)
KR (1) KR20240139085A (enExample)
AU (1) AU2023219227A1 (enExample)
CA (1) CA3258958A1 (enExample)
CL (1) CL2024002361A1 (enExample)
CO (1) CO2024010901A2 (enExample)
IL (1) IL314314A (enExample)
MX (1) MX2024009898A (enExample)
WO (1) WO2023152486A1 (enExample)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2013221502C1 (en) * 2012-02-14 2018-03-01 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies

Also Published As

Publication number Publication date
US20250340659A1 (en) 2025-11-06
KR20240139085A (ko) 2024-09-20
IL314314A (en) 2024-09-01
CO2024010901A2 (es) 2024-10-31
MX2024009898A (es) 2024-08-20
CL2024002361A1 (es) 2024-11-29
EP4476256A1 (en) 2024-12-18
CA3258958A1 (en) 2023-08-17
AU2023219227A1 (en) 2024-08-01
WO2023152486A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
US20230272097A1 (en) Therapeutic antibodies
JP7303126B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
JP6938383B2 (ja) イヌインターロイキン４受容体アルファに対する抗体
JP7254699B2 (ja) 抗ｂｃｍａ重鎖のみ抗体
CA2861793C (en) Method of providing monoclonal auto-antibodies with desired specificity
US11814426B2 (en) Anti-tenascin C antibodies and uses thereof
US10131709B2 (en) Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
KR20140041858A (ko) 인터루킨-31 단클론성 항체
WO2022117079A1 (zh) 结合胸腺基质淋巴细胞生成素的抗体及其应用
KR20240026185A (ko) 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도
US20250340659A1 (en) Therapeutic antibodies
CN118715244A (zh) 治疗性抗体
KR20230079074A (ko) 면역글로불린 ｅ 항체 조성물 및 사용 방법
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
RU2795411C2 (ru) Моноклональные антитела к интерлейкину-31 для ветеринарного применения
CN120842422A (zh) 一种抗CD30和CD16a的双特异性抗体及其应用
CN121532424A (zh) Btn3a结合蛋白及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260122